Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Phase 1 Active not recruiting 37 enrolled City of Hope Medical Center National Cancer Institute (NCI) · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of cellular immunotherapy following chemotherapy in treating patients with non-Hodgkin lymphomas, chronic lymphocytic leukemia, or B-cell prolymphocytic leukemia that has come back. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.

Timeline

Start: 2014-09-24
Primary completion: 2026-09-02
Completion: 2026-09-02

Publications

Siddiqi T, Wang X, Blanchard MS, Wagner JR, Popplewell LL, Budde LE, Stiller TL, Clark MC, Lim L, Vyas V, Brown CE, Forman SJ. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 2021 Oct 26;5(20):4059-4063. doi: 10.1182/bloodadvances.2020004106.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes	Cell therapy	—	Intravenous
Background	Bendamustine	Small molecule	—	Intravenous
Background	Cyclophosphamide	Other / unclassified	—	Intravenous
Background	Etoposide	Small molecule	—	Intravenous
Background	Fludarabine	Small molecule	—	Intravenous

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Summary

Timeline

Publications

Drugs

Indications